other material
confidence high
sentiment neutral
materiality 0.60
Cadrenal stockholders approve reverse split, share increase, and equity plan amendment
Cadrenal Therapeutics, Inc.
- Approved reverse stock split at Board's discretion (1:2 to 1:20 ratio).
- Authorized share increase from 75M to 125M shares of common stock.
- Equity plan amendment adds 2,000,000 shares (total 4,604,550) and modifies evergreen provision to 20% of outstanding plus warrant shares.
- Elected directors John Murphy and Robert Lisicki to Class II until 2027.
- Ratified WithumSmith+Brown as independent auditor for 2024 fiscal year.